Partnership / Collaboration · GCC · Announced 2 Nov 2026
Roche Pharmaceuticals UAE → Department of Health – Abu Dhabi
Roche Pharmaceuticals UAE and Abu Dhabi's Department of Health agreed a strategic collaboration using real-world evidence to map and improve early detection, referral and treatment of diabetic macular edema in the emirate; terms undisclosed.
Parties: Roche Pharmaceuticals UAE (Switzerland) → Department of Health – Abu Dhabi (United Arab Emirates)
- Deal type
- Partnership / Collaboration
- Value
- Undisclosed
- Territory
- Abu Dhabi, United Arab Emirates
- Therapeutic area
- Ophthalmology
- Asset
- Diabetic macular edema real-world evidence programme
- Announced
- 2 Nov 2026
Our analysis
Why this matters
Roche Pharmaceuticals UAE and the Department of Health – Abu Dhabi (DoH) have announced a strategic collaboration on diabetic macular edema (DME), the diabetes-related retinal condition that is a leading cause of vision loss in working-age adults. The programme will use real-world evidence (RWE) to analyse current care pathways in Abu Dhabi — early detection, diagnosis, referral, treatment and follow-up — together with clinical outcomes and resource use. A joint working group will oversee implementation and capacity building. Coverage published on 2 November 2026 links the announcement to the Abu Dhabi Future Health Summit 2026. No financial terms, timelines or patient numbers were disclosed, and no specific product is named.
The deal extends an existing relationship. DoH and Roche Middle East signed an MoU in May 2024 on RWE and rare diseases, and in 2025 Roche announced a three-year partnership with the Abu Dhabi Public Health Centre covering early detection of lung cancer and DME.
The full analysis is free to read with a work email on this page.